Advertisement

© 2020

Reviews on New Drug Targets in Age-Related Disorders

  • Paul C. Guest
Book

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1260)

Also part of the Proteomics, Metabolomics, Interactomics and Systems Biology book sub series (PMISB, volume 1260)

Table of contents

  1. Front Matter
    Pages i-viii
  2. Lixia Gao, Jenni Loveless, Chloe Shay, Yong Teng
    Pages 1-12
  3. Behnaz Abiri, Mohammadreza Vafa
    Pages 13-31
  4. Undurti N. Das
    Pages 33-83
  5. Mariane Font Fernandes, Sarah de Oliveira, Mariana Portovedo, Patrícia Brito Rodrigues, Marco Aurélio Ramirez Vinolo
    Pages 85-105
  6. Vasily V. Ashapkin, Lyudmila I. Kutueva, Boris F. Vanyushin
    Pages 107-122
  7. Gabriel Nasri Marzuca-Nassr, Yuri SanMartín-Calísto, Pablo Guerra-Vega, Macarena Artigas-Arias, Andrea Alegría, Rui Curi
    Pages 123-158
  8. Aliza K. De Nobrega, Kristine V. Luz, Lisa C. Lyons
    Pages 193-265
  9. Madia Lozupone, Maddalena La Montagna, Francesca D’Urso, Carla Piccininni, Angelo Rinaldi, Massimiliano Beghi et al.
    Pages 267-281
  10. S. Agatonovic-Kustrin, E. Kustrin, V. Gegechkori, D. W. Morton
    Pages 283-296
  11. Behnaz Abiri, Mohammadreza Vafa
    Pages 297-318
  12. Veronika Piskovatska, Kenneth B. Storey, Alexander M. Vaiserman, Oleh Lushchak
    Pages 319-332
  13. Back Matter
    Pages 333-340

About this book

Introduction

Aging is an inevitable part of life and is becoming a worldwide social, economic and health problem. This is mainly due to the fact that the increasing proportion of individuals in the advanced age category have a higher probability of developing age-related disorders, such as type II diabetes mellitus, cardiovascular disorders, sarcopenia, and neurodegenerative conditions. New therapeutic approaches are still needed to decrease or slow the effects of such diseases. Advances in -omic technologies, such as genomics, transcriptomics, proteomics and metabolomics, have significantly advanced our understanding of disease in multiple medical areas, as the analysis of multiple molecular networks has simultaneously provided a more integrated view of disease pathways. It is hoped that emerging hits from these analyses might be prioritized for further screening as potential novel drug targets for increasing the human healthspan in line with the lifespan. In turn, this will lead to new therapeutic strategies as well as drug development projects by the pharmaceutical industry.

This book presents a series of reviews describing studies that have resulted in identification of new potential drug targets for age-related disorders. Much of this information has come from -omic comparisons of healthy and disease states or from testing the effects of new therapeutic approaches. Authored by experts from around the globe, each chapter is presented in the context of specific chronic diseases or therapeutic strategies. This book is designed for researchers in the areas of aging and chronic disease, as well as clinical scientists, physicians and stakeholders in major drug companies. 

Keywords

age-related diseases parabiosis bioactive lipids Alzheimer’s disease Metformin

Editors and affiliations

  • Paul C. Guest
    • 1
  1. 1.Laboratory of Neuroproteomics, Department of Biochemistry and Tissue BiologyInstitute of Biology, University of Campinas (UNICAMP)CampinasBrazil

About the editors

Dr. Paul C. Guest, Ph.D, is a scientific researcher/writer with 37 years of experience in the fields of metabolic and neurological disorders. This includes experience in both academia and the pharmaceutical industry with the majority of time spent at the University of Cambridge and Merck Sharp & Dohme in the United Kingdom. He has also been affiliated with the University of Campinas in Sao Paulo Brazil since 2015, still focused on advancing the field of biomarkers for neurological disorders such as schizophrenia and age-related diseases such as diabetes, cancer, cardiovascular disorders, sarcopenia and Alzheimer’s disease. 

Bibliographic information

Industry Sectors
Biotechnology
Pharma